What is the average amount of weight gain when taking valproate or valproic acid?
Best insight from top research papers
On average, when taking valproate or valproic acid, the amount of weight gain varies based on the duration of treatment and the specific drug used. Studies have shown that weight gain is a common adverse effect of sodium valproic acid (VPA) in children with epilepsy, with significant increases observed in body mass index (BMI) and weight over time . In adults, valproate monotherapy has been associated with a substantial increase in weight, significantly higher than that seen with lamotrigine treatment . The weight gain typically starts within 10 weeks of initiating valproate therapy and continues to rise steadily throughout the treatment period . Therefore, it is crucial to monitor weight changes regularly when using these medications, especially in pediatric and adult populations with epilepsy.
Answers from top 4 papers
More filters
| Papers (4) | Insight |
|---|---|
208 Citations | Patients taking valproate experienced significantly higher weight gain compared to those on lamotrigine, with an average of 12.8 ± 9.3 lb versus 1.3 ± 11.9 lb, respectively. |
23 Citations | Patients on valproic acid treatment showed significantly higher weight gain compared to those on lamotrigine, with an average weight of 64.88±3.25 in the valproic acid group. |
| Children on sodium valproate experienced a statistically significant weight gain, with the average increase being from 18.54 kg to 21.13 kg after six months of treatment. | |
1 Citations | The study found a significant weight gain in pediatric patients with epilepsy treated with valproic acid over 36 to 48 months, emphasizing the need for nutritional support. |
Related Questions
How do these side effects compare to those of valproate in the same patient population?5 answersValproate, a commonly used antiepileptic drug, is associated with various side effects in patients. These include nocturnal enuresis and daytime incontinence, rest tremor, parkinsonism, hyperammonemic encephalopathy, sedation, tremor, gastrointestinal effects, weight gain, alopecia, abdominal discomfort, thrombocytopenia, hepatotoxicity, coagulation disorders, and rhabdomyolysis. Studies have shown that around 11.2% of patients treated with valproate experience rest tremor, with a small percentage developing parkinsonism. Additionally, valproate-induced hyperammonemic encephalopathy can occur, necessitating careful monitoring and management. Notably, rapid onset adverse effects like rhabdomyolysis have been reported within 24 hours of valproate initiation, emphasizing the need for close monitoring of patients. Overall, valproate exhibits a range of side effects affecting various systems in the same patient population.
How does the administration of chlorpromazine affect weight compared to quetiapine?4 answersThe administration of chlorpromazine is associated with significant weight gainand increased concentrations of cholesterol, triglycerides, and body weight. On the other hand, quetiapine has been found to induce weight loss in some patients who gained weight during previous antipsychotic treatments. Quetiapine has a lower impact on blood glucose and weight compared to chlorpromazine. Additionally, quetiapine has been linked to a lower incidence of adverse effects related to weight gain and endocrine changes when compared to chlorpromazine. Therefore, while chlorpromazine is associated with weight gain and metabolic alterations, quetiapine appears to have a more favorable profile in terms of weight effects and metabolic parameters.
How does weight affect dosing of NOACs?5 answersWeight affects the dosing of non-vitamin K antagonist oral anticoagulants (NOACs). In patients with lower body weight, fixed doses of NOACs can lead to suboptimal plasma concentrations, particularly with dabigatran and rivaroxaban. Dose reduction is recommended for apixaban in patients with body weight ≤ 60 kg. On the other hand, in patients with higher body weight, fixed doses of NOACs can result in higher drug exposure and blood drug levels. The International Society on Thrombosis and Haemostasis suggests that NOACs are safer in patients with body weight ≤ 120 kg (BMI ≤ 40 kg/m2) compared to patients with body weight > 120 kg (BMI > 40 kg/m2). However, the efficacy and safety of NOACs in patients at the extremes of body weight remain uncertain. More data is needed to determine the optimal dosing of NOACs in patients with extreme body weight changes.
How valproic acid cause pancreaitis?4 answersValproic acid can cause pancreatitis through various mechanisms. It is believed that valproic acid or its metabolites can directly damage the pancreas, leading to inflammation and pancreatitis. Additionally, valproic acid may induce hypersensitivity reactions in the pancreas, causing injury and inflammation. The exact mechanisms by which valproic acid induces pancreatitis are not fully understood, but it is thought to involve oxidative stress, mitochondrial dysfunction, and disruption of cellular signaling pathways. Valproic acid-induced pancreatitis is a rare adverse effect, but it can be severe and potentially life-threatening. Therefore, it is important for clinicians to be aware of this potential complication and monitor patients receiving valproic acid therapy for any signs or symptoms of pancreatitis.
Does valproic acid improve seizure control in children with spina bifida?5 answersValproic acid does not improve seizure control in children with spina bifida.
How much weight is gained when using mirtazapine?5 answersMirtazapine has been associated with weight gain in several studies. In a study of healthy males, a seven-day administration of mirtazapine resulted in a significant decrease in weight and BMI. Another study in cats experiencing unintended weight loss found that treatment with mirtazapine resulted in significant weight gain. In a study of diabetic patients, mirtazapine treatment led to an increase in body mass index. Additionally, a study in nondepressed patients with cancer-related cachexia/anorexia found that some patients gained weight after eight weeks of mirtazapine treatment. Overall, the use of mirtazapine has been consistently associated with weight gain in various populations.